Curcumin exerts distinct anti-tumor effects mediated by NRF1α from NRF2 via metabolic reprogramming in hepatocellular carcinoma (HepG2).
Wufuer Reziyamu, Feng Jing, Hu Shaofan, Wang Meng, Liu Keli, Zhang Yiguo
Abstract
NRF1α and NRF2, two CNC-bZIP transcription factors, regulate redox homeostasis and metabolic stability, forming a precisely coordinated regulatory network in HCC characterized by functional complementarity and directional antagonism. Although curcumin (CUR), a dietary polyphenol, exerts pleiotropic anti-cancer effects, its clinical application is limited by low bioavailability and undefined molecular targets. This study hypothesized that CUR acts through differential regulation of NRF1α/NRF2-mediated signaling, with NRF1α as the primary effector in HCC. Firstly, we confirmed direct CUR-NRF1α interaction, and CUR stabilizes NRF1α through suppressing proteasomal degradation. Subsequently experiments, using a panel of isogenic HepG2 cell lines (wild-type, NRF1α-∕-, NRF2-∕-) and xenograft models, we characterized the dose-dependent effects of CUR on NRF1α expression and systematically compared its downstream pathways involved in oxidative stress resistance and metabolic regulation. CUR exhibited genotype-dependent biphasic effects: it synergistically activated both NRF1α and NRF2 in WT cells, but paradoxically inhibited hyperactive NRF2 in NRF1α-deficient cells. NRF1α mediated the core tumor-suppressive functions via metabolic reprogramming and alleviation of oxidative stress, whereas NRF2 contributed to residual protective effects in the absence of NRF1α. Notably, the anti-tumor efficacy of CUR was largely dependent on intact NRF1α signaling. In xenograft models, CUR showed modest single-agent activity but induced synthetic lethality in NRF1α-deficient tumors by inhibiting NRF2. Collectively, NRF1α acts as the primary effector of CUR in HCC, offering new mechanistic insights. These findings support the development of NRF1α-selective CUR derivatives and highlight NRF1 expression as a candidate predictive biomarker.
Key Findings
- Curcumin directly interacts with and stabilizes NRF1α by suppressing its proteasomal degradation.
- Curcumin exerts genotype-dependent biphasic effects by synergistically activating both NRF1α and NRF2 in wild-type HepG2 cells, but inhibiting hyperactive NRF2 in NRF1α-deficient cells.
- The anti-tumor efficacy of curcumin in hepatocellular carcinoma is largely dependent on intact NRF1α signaling, with NRF1α mediating core tumor-suppressive functions via metabolic reprogramming and oxidative stress alleviation.
Clinical Significance
These findings highlight NRF1α as a primary effector and potential predictive biomarker for curcumin treatment in hepatocellular carcinoma, supporting development of NRF1α-selective curcumin derivatives to improve therapeutic efficacy.
Citation
Wufuer Reziyamu, Feng Jing, Hu Shaofanet al.. Curcumin exerts distinct anti-tumor effects mediated by NRF1α from NRF2 via metabolic reprogramming in hepatocellular carcinoma (HepG2). Bioorganic chemistry. 2026-Oct-05.